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Abstract In Metazoans a number of cellular functions are
controlled by receptor tyrosine kinases (RTKs) during develop-
ment and in postnatal life. The execution of these programs
requires that signals of adequate strength are delivered for the
appropriate time within precise spatial boundaries. Several RTK
inhibitors have been identified in invertebrate and mammalian
organisms. Because they are involved in tuning and termination
of receptor signals, negative regulators of RTK activity ful-
fill a fundamental function in the control of receptor signa-
ling. ß 2001 Federation of European Biochemical Societies.
Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
In multicellular organisms receptor tyrosine kinases (RTKs)
are involved in the control of fundamental aspects of cell
physiology, ranging from cell migration to survival, growth,
proliferation and di¡erentiation. Once bound by their cognate
ligand, RTKs dimerize and become catalytically active. The
earliest consequence of dimerization-based RTK activation is
receptor trans-phosphorylation on speci¢c tyrosine residues:
this process generates recognition codes for signaling proteins
containing PTyr binding modules (SH2 and PTB domains)
[1,2] (Fig. 1A,B).
The nucleation of these complexes onto activated receptors
allows transmission of receptor signals to speci¢c pathways,
due to the fact that PTB and SH2 domains are present in
either enzymes (e.g. c-src, PLC-Q, PI-3K, Ras-GAP etc.) or
adapter proteins (e.g. GRB-2). Recruitment of enzymes onto
RTKs leads to their activation by virtue of three mechanisms:
(a) direct phosphorylation on speci¢c tyrosine residues; (b)
allosteric changes induced by PTyr-directed protein^protein
interactions; (c) recruitment to the plasma membrane, i.e. to
a subcellular compartment where substrates are available.
Adapter proteins are devoid of intrinsic catalytic activities
but regulate downstream enzymes via further protein^protein
interactions [1,2] (Fig. 1C). A variation of this paradigm is the
extensive phosphorylation by RTKs of membrane-located
sca¡old proteins (e.g. IRS proteins and GAB-1) which, sim-
ilarly to autophosphorylated RTKs, serve as platforms for the
assembly of complexes of signaling proteins containing PTB
and SH2 domains [1].
These networks of protein^protein interactions allow for
rapid, spatially controlled and reversible activation of signal-
ing pathways downstream to RTKs. They also allow for
quantitative control of signaling by providing for either am-
pli¢cation or insulation of signals. Last, but not least, the
presence of several protein^protein interaction modules in
multi-domain signaling proteins is instrumental in regulating
integration of signals among di¡erent pathways [3].
Despite structural diversi¢cation, most RTKs activate
broadly overlapping sets of signaling pathways. Thus, a major
issue in the ¢eld of cell signaling is how di¡erent RTKs in-
struct cells to adopt speci¢c fates [4]. The identity of the
responding cell, i.e. its developmental history, is a major fac-
tor in determining the outcome of a given signal or set of
signals. Accordingly, activation of Trk-A, the high a⁄nity
receptor for nerve growth factor (NGF), elicits mitogenic
and transforming signals in murine ¢broblasts whereas drives
neuronal di¡erentiation of pheochromocytoma-derived PC12
cells. In such an example Trk-A signals impinge on qualita-
tively di¡erent cellular machineries, e.g. transcription factors,
which are geared to execute fundamentally di¡erent programs.
In a more re¢ned version of this theme it is the integration of
a ‘generic’ RTK signal with that emanating from another
receptor, e.g. Notch, which generates the speci¢c cellular re-
sponses that fate the cell [4].
More challenging to be resolved at the molecular level is the
scenario in which di¡erent biological responses may be in-
duced in the same cell by the same signal, depending on the
magnitude and duration of the latter. Cultured PC12 cells
serve again as a paradigm to understand cell behavior in mo-
lecular terms. A short wave of ERK activation, as elicited by
epidermal growth factor (EGF) stimulation, drives PC12 cells
to proliferate, whereas lengthy ERK activation, as obtained
with NGF treatment, causes PC12 cells to di¡erentiate [5].
Along the same line, graded levels of ERK activity pattern
the posterior termini of Drosophila melanogaster embryos.
Here the Torso RTK is activated by its ligand Trunk. As
Trunk is produced in limiting amounts by a localized source,
its di¡usion establishes a gradient, which leads to di¡erent
levels of Torso occupancy and to correspondingly graded
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levels of Torso-dependent ERK activity [6]. At the posterior
pole of the embryo this is translated into di¡erent transcrip-
tional responses: huckebein is expressed where ERK activity is
greatest, whereas the domain of expression of tailless extends
into regions of lower ERK activity. Gradients of hkb and tll in
turn regulate downstream target genes which are thought to
implement distinct morphogenetic responses [7,8].
Because variations in strength and duration of a given sig-
nal are means to convey di¡erent instructions to a cell, mech-
anisms have evolved which ensure that appropriate thresholds
of signal are achieved and maintained for the right time. It
follows that generation, tuning and termination of signals
must be viewed as integrated processes which organize in
time and space the correct output of any given signal.
The purpose of this review is to discuss the role of negative
regulators of RTK signaling in establishing appropriate
thresholds of biochemical responses to receptor activation.
Protein tyrosine phosphatases (PTPs) reverse RTK signals
by dephosphorylating RTK substrates: hence the activity of
PTPs is an e¡ective measure of counteracting RTK signals.
The role of PTPs in RTK signaling has been the subject of
recent reviews to which the reader is therefore referred [9,10].
Here we will brie£y discuss how negative regulators of RTK
signals in£uence developmental processes in invertebrates. We
will then focus on structural and functional features of mol-
ecules which interact physically with mammalian RTKs and
attenuate receptor signaling.
2. Lessons from developmental biology of invertebrates
Developmental studies in Caenorhabditis elegans and D.
melanogaster have provided compelling evidence that negative
regulation of RTK signaling is required to ensure proper fate
determination and patterning.
In C. elegans induction of the vulva depends on the local-
ized activity of Lin-3, a member of the EGF family of growth
factors, which is produced by the anchor cell (AC) [11]. Lin-3
instructs three out of six vulva precursor cells (VPCs), which
lay beneath the AC, to proliferate and di¡erentiate, thus
forming the mature vulva (Fig. 2). Several lines of evidence
Fig. 1. Signaling by RTKs. A: In the absence of ligand stimulation RTKs are present as catalytically silent monomers. B: Ligand binding in-
duces productive dimerization of RTKs which is followed by catalytic activation and receptor cross-phosphorylation on speci¢c tyrosine resi-
dues. C: Phosphotyrosine residues on activated RTKs serve as docking sites for e¡ectors such as the enzyme phospholipase C-Q (PLC-Q). Bind-
ing to activated RTKs induces translocation of PLC-Q from cytosol to the plasma membrane and enhances tyrosine phosphorylation of PLC-Q
by RTKs: both steps are necessary for full catalytic activation of PLC-Q which leads to hydrolysis of PIP2 to IP3 and DAG. Phosphotyrosine
residues on activated RTKs may serve as docking sites also for adapters such as GRB-2. This leads to translocation of the cytosolic GRB-2/
SOS complex to the plasma membrane, thus allowing the guanyl-nucleotide exchanger SOS to target its substrate Ras.
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indicate that the distance of the AC from VPCs establishes a
gradient of Lin-3 activity, with P6.p receiving a stronger sig-
nal than P5.p and P7.p [12]. As a consequence, P5.p and P7.p
adopt a 2‡ fate, whereas the highest dose of Lin-3 instructs
P6.p to adopt a 1‡ fate. Lin-3 activates LET-23, a C. elegans
homolog of EGFR; LET-23 binds Sem-5/GRB-2 which sig-
nals to LET-60/Ras [11,13].
Restricted availability of Lin-3 is instrumental in generating
a spatially de¢ned pattern of VPC fates. Disruption of this
balance by excess Lin-3CLET-23CLET-60 activity leads to
a multivulva phenotype, caused by recruitment of extra VPCs
to the vulval fate. The implication of these ¢ndings is that
LET-23 activity must be held in check. Genetic studies indi-
cate that negative regulators of receptor signals, such as
sli-1/cbl [14], gap-1/RasGAP [15] and ARK-1 [16], are key
players in the modulation of LET-23 activity. Hence, the ac-
tivity of negative regulators of the LET-23CLET-60 pathway
integrates the restricted availability of Lin-3 to establish pre-
cise thresholds of signals.
In mammalians, c-Cbl has ubiquitin E3 ligase activity and
interacts physically with the EGFR to promote its ubiquitini-
lation and subsequent degradation ([17^19], for review see
Waterman and Yarden, this issue of FEBS Lett.). By analogy,
sli-1 is thought to dampen LET-23 signaling by promoting its
down-regulation. Gap-1 inhibits LET-60 by accelerating its
GTPase activity, thus locking LET-60 in the inactive GDP-
bound state. ARK-1 is related to the mammalian tyrosine
kinase ACK [20]; how ARK-1 signals to LET-23 has not
been determined, due also to the fact that the function of
ACK in mammals remains elusive. It is clear however that
ARK-1 requires Sem-5/GRB-2 for negative signaling to
LET-23 [16]. The genetic interaction between ARK-1 and
Sem-5 may be explained by the ¢nding that the two proteins
form a physical complex in yeast two hybrid experiments.
Therefore it is thought that ARK-1 may inhibit LET-23 ac-
tivity by being recruited to the receptor in a complex with
Sem-5/GRB-2 [16]. This model implies that Sem-5 can exert
opposite e¡ects on the LET-23CLET-60 pathway, presum-
ably by forming complexes with di¡erent e¡ectors.
As in C. elegans, a homolog of EGFR in D. melanogaster
also regulates a number of developmental processes by trig-
gering a conserved signaling cassette which leads to Ras acti-
vation [21]. Since DER (Drosophila EGF receptor) is ubiqui-
tously expressed, restricted availability of its ligands (Gurken,
Vein and Spitz) and tight regulation of its activity in time and
space are required to ensure accurate execution of develop-
mental programs. Genetic studies have revealed that a crucial
role in the regulation of DER activity is played by inhibitors
of receptor function which are expressed in the context of
transcriptional responses triggered by DER itself (Fig. 3).
Argos is a soluble molecule which carries a modi¢ed EGF
domain and binds the extracellular region of DER. Once
bound to Argos, DER is prevented from binding Spitz and
dimerizing (Fig. 3): hence Argos inhibits crucial steps leading
to catalytic activation of DER [22].
The role of Argos in patterning the embryo ventral ecto-
derm is an example of how Argos expression contributes to
the spatial and temporal control of signaling by the DER
RTK. Regulated cleavage of membrane-bound Spitz along
the ventral midline of the Drosophila embryo activates
DER. Because soluble Spitz is produced in limiting amounts,
its di¡usion leads to graded DER activation: in turn, graded
DER activity patterns the ventral ectoderm [23]. Argos is tran-
scribed in cells in which DER itself is activated most strongly.
Di¡usion of Argos from its site of production leads to inhi-
bition of DER signaling in neighboring cells. If Argos expres-
sion is ablated, cells in which DER is normally activated at
intermediate to low levels end up receiving a stronger Spitz
signal for a longer time. This leads to ventralization of the
ectoderm, i.e. the expansion of the domain in which cells
adopt the ventralmost fate [23]. Thus, by di¡using in the do-
main of Spitz activity, Argos re¢nes the Spitz gradient and
maintains the graded levels of DER activity required for pat-
terning the ventral ectoderm.
Kekkon1 typi¢es a di¡erent class of feedback inhibitors of
DER. During oogenesis, localized production of Gurken in
the dorsal-anterior region of the oocyte leads to activation of
DER in the surrounding follicular cells. DER signaling leads
to expression of rhomboid whose product enhances Spitz
cleavage: this establishes an autocrine loop which boosts
DER signaling and broadens the domain of DER activity
[24]. Cells located in the initial domain of Gurken and Spitz
activity receive the highest signal and produce Argos which, in
turn, acts locally to inhibit DER signaling. As a consequence,
the domain of DER activity is split into two symmetric peaks
which pattern the dorsal appendages [24]. Kekkon 1 was iden-
ti¢ed as a gene transcriptionally activated by DER signaling
during oogenesis [25]. Overexpression of kekkon 1 leads to
loss of dorsal appendages (as observed upon loss of gurken
and egfr), whereas its genetic ablation causes lateral expansion
of dorsal appendages, i.e. broadening of the domain of DER
activity. These phenotypes coupled to epistatic analysis indi-
cate that Kekkon 1 inhibits DER signaling at the receptor
level [25]. Kekkon 1 is a transmembrane protein which is
able to interact with DER and has features similar to those
of cell adhesion molecules. Overexpression of a truncated
Kekkon 1 mutant spanning the extracellular and transmem-
brane domains is su⁄cient to cause inhibition of DER. Hence
it has been proposed that Kekkon 1 exerts its function by
virtue of a physical interaction with DER, which leads to
direct or indirect inhibition of DER signaling (Fig. 3) [25].
A third feedback inhibitor of DER is sprouty. Sprouty was
Fig. 2. Model of vulva development in C. elegans. The AC produces
the EGF-like factor Lin-3. VPC receive di¡erent doses of Lin-3, de-
pending on their distance from the AC. Under normal conditions,
P6.p receives the highest dose (long and thick arrow) and adopts a
1‡ fate, whereas P5.p and P7.p receive a lower dose (short arrows)
and adopt a 2‡ fate. The mature vulva is eventually generated by
three rounds of proliferation of 1‡ and 2‡ fate VPCs. Reduction of
function mutations of negative regulators of the Lin-3CLET-
23CLET-60 pathway cause recruitment to vulval fate of extra
VPCs (i.e. P3.p or P4.p or P8.p).
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originally cloned as a feedback inhibitor of breathless, a
Drosophila FGF receptor [26]. During branching morphogen-
esis of the respiratory tree, sprouty expression is induced in
cells receiving the highest level of Branchless, an FGF-like
ligand which acts locally to induce branching of tracheal ep-
ithelium. The sprouty product, in turn, acts non-cell autono-
mously to repress Breathless signaling in neighboring cells.
This spatial restriction of Breathless activity ensures that
only cells which are closest to the source of activating ligand
are induced to branch; this allows the reproduction of precise
patterns of airway branching [27].
Sprouty expression is induced also by DER activity,
although not in all tissues. Loss of sprouty expression in the
eye causes increased recruitment of photoreceptor and non-
photoreceptors cells, a phenotype associated with excess DER
signaling [28]. At variance with tracheal branching, the
sprouty phenotype in the eye is cell autonomous. Loss of
sprouty causes hyperactivation of DER also in the egg, lead-
ing to expansion of the dorsal appendage fate laterally and
into the inter-appendage region [29]. The reduction of inter-
appendage region upon sprouty loss is interesting, because
argos is still expressed under these conditions: this implies
that Argos and Sprouty act cooperatively in repressing DER
activity in this domain [29].
At variance with Argos and Kekkon 1, which appear to be
speci¢c for DER, Sprouty is promiscuous in that it inhibits
also signaling from other RTKs such as Breathless, Torso and
possibly Sevenless [28,29]. The promiscuity of Sprouty as an
inhibitor of RTK signaling to the RasCERK pathway may
be explained by its structural features. Sprouty is an intra-
cellular protein (Fig. 3) which localizes to the inner surface
of the plasma membrane via a Cys-rich domain and binds to
Drk/GRB-2 and Gap-1/RasGAP [28]. The current model
holds that Sprouty constitutive location in the plasma mem-
brane may regulate the availability and/or function of cyto-
solic signal transducers recruited by activated RTKs to signal
to Ras (Fig. 3).
3. Negative regulation of RTK signaling in mammalian cells
As in the case of nematodes and £ies, inhibitory molecules
in mammalian organisms may also target RTK signaling cas-
settes at di¡erent steps.
Herstatin is a secreted protein encoded by an alternatively
spliced form of the HER-2/erbB-2 mRNA [30]. This splicing
event generates a 274 nt insertion contiguous to exon 9 se-
quences. The resulting reading frame causes translation termi-
nation at the end of a 79 aa in frame insertion which is fused
to the ¢rst 340 residues of ErbB-2: thus, Herstatin encodes a
soluble protein which contains subdomain I and II of ErbB-2
extracellular domain [30] (Fig. 4). Herstatin binds to
gp185ErbBÿ2 with high a⁄nity and inhibits dimerization and
catalytic activation of ErbB-2. Consistently with these bio-
chemical observations, addition of Herstatin to the culture
Fig. 3. Feedback inhibition of EGFR signaling in Drosophila. DER signals through the Ras/ERK pathway and induces expression of Argos,
Kekkon1 and Sprouty. Argos is a secreted molecule which binds to the extracellular domain of DER and prevents DER activation by Spitz.
Kekkon1 is a transmembrane protein which is thought to interfere with DER activation and/or signaling by binding to the receptor. Sprouty is
anchored to the inner surface of the plasma membrane and binds to signal regulators such as Gap and Drk: it is speculated that Sprouty either
acts as a sink for positive e¡ectors or enhances the function of negative regulators of RTK signaling (e.g. Ras GAP).
FEBS 24566 14-2-01 Cyaan Magenta Geel Zwart
M. Fiorini et al./FEBS Letters 490 (2001) 132^141 135
medium causes inhibition of anchorage-independent growth
of NIH-ErbB-2 transfectants [30]. Although it has not been
reported whether Herstatin inhibits binding of NDF (or other
ligands) to ErbB heterodimers containing ErbB-2, it seems
likely that Herstatin may have functions similar to those of
Argos (Fig. 5A). It is not clear how the expression of the
alternative transcripts encoding Herstatin is regulated. How-
ever it appears that expression of Herstatin may be modulated
during development: Herstatin transcripts were detected in
fetal kidney but not in fetal brain and lung. ErbB receptors
are implicated in branching morphogenesis of the kidney [31].
Because branching morphogenesis requires reiterated and
tightly regulated cycles of migration, proliferation and di¡er-
entiation, one can imagine that Herstatin expression may con-
tribute to spatial regulation of ErbB receptor activity during
kidney morphogenesis.
As mentioned above, sli-1, a homolog of mammalian c-cbl,
was discovered as a negative regulator of Let-23 activity in C.
elegans. Cbl contains an NH2-terminal phosphotyrosine bind-
ing domain, a RING ¢nger domain, Pro-rich sequences and a
COOH-terminal leucine-zipper (Fig. 4). Biochemical studies
have shown that the RING ¢nger domain of c-Cbl (Fig. 4)
has E3 ubiquitin ligase activity [17,18]. Cbl is recruited to the
EGFR upon receptor activation and becomes phosphorylated
on a tyrosine residue adjacent to the RING ¢nger domain.
This leads to activation of the ubiquitin E3 ligase function of
c-Cbl [18] (Fig. 5B). The ensuing polyubiquitination of EGFR
targets the receptor to the internalization and degradation
pathway, thus contributing to signal attenuation (reviewed
in Waterman and Yarden, this issue of FEBS Lett.). Over-
expression of c-Cbl has been shown to also inhibit mitogenic
activity of PDGF-R [32]; conversely microinjection of anti-
Cbl antibodies enhanced mitogenic response to sub-optimal
doses of PDGF [32]. Cbl is also implicated in internalization
of the CSF-1 receptor [33]. Thus c-Cbl is involved in negative
regulation of several RTKs.
Herstatin and c-Cbl are examples of negative regulators of
RTK activity that are likely to dampen the entire breadth of
receptor signaling. In contrast, a number of adapters have
been identi¢ed in the past couple of years that appear to be
involved in negative regulation of speci¢c pathways triggered
by RTKs.
APS, Lnk and SH2-B represent a family of structurally and
functionally related adapters involved in negative regulation
of RTKs and cytokine receptors [34]. All three family mem-
bers share a common structural organization, consisting of an
NH2-terminal region containing potential binding sites for
SH3 domains, a PH domain, an SH2 module and a COOH
tail containing a conserved tyrosine phosphorylation site [34].
Signaling by APS (adapter containing PH and SH2 domains,
Fig. 4. Structural features of mammalian proteins involved in negative regulation of RTK signaling. The extracellular domain of ErbB-2 com-
prises sub-domains I to IV. TM, KD and COOH indicate the transmembrane, kinase and C-terminal domains, respectively. Herstatin is en-
coded by an alternatively spliced ErbB-2 mRNA which generates a secreted protein containing sub-domains I and II of ErbB-2 and a C-termi-
nal novel sequence of 79 residues. c-Cbl contains a phosphotyrosine binding domain (PTB), a RING ¢nger (RF) domain, two Proline-rich
regions (PRO) and a leucine zipper (LZ). APS contains PH and SH2 domains, in addition to a Pro-rich region. Slap contains a myristoylation
signal at its NH2-terminus and consists of SH3 and SH2 domains followed by a COOH-terminal tail of about 100 residues. RALT contains
two blocks of PEST sequences, an ErbB-2 binding region and a potential nuclear localization signal (NLS); several Pro-rich sequences targeted
by SH3 domains are also present in the RALT protein. SOCS proteins consist essentially of a SH2 domain and a C-terminal SOCS box.
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see Fig. 4) has been studied in some detail in the context of
PDGF-R activation [35]. Upon PDGF stimulation, APS
binds via its SH2 domain to PTyr 1021 of the LPDGF-R, is
phosphorylated on a tyrosine residues in its COOH tail and is
relocated to the plasma membrane. Tyrosine-phosphorylated
APS in turn binds to GRB-2 and to c-Cbl. Overexpression of
APS in NIH 3T3 ¢broblasts inhibited mitogenic signaling
induced by PDGF. The biological e¡ects of APS overexpres-
sion correlated with inhibition of fos and myc transcription
induced by PDGF; importantly, PDGF-R signaling to the
PI-3 kinase complex was not altered by APS overexpression
[35]. An APS mutant lacking the COOH tail was not phos-
phorylated on tyrosine upon PDGF-R triggering, did not bind
c-Cbl and did not inhibit PDGF-dependent mitogenesis when
overexpressed in 3T3 cells. Binding of c-Cbl to APS enhanced
the inhibitory activity of the latter on fos transcription; this
e¡ect was reversed by deletion of the Tyr residue involved in
the recruitment of c-Cbl onto APS. Thus it appears that the
inhibitory function of APS on PDGF-R signaling requires
recruiting of c-Cbl in a PTyr-dependent complex with APS
itself [35] (Fig. 5B). It is possible that recruitment of APS to
the plasma membrane is initially mediated by its interaction
with the PDGF-R and subsequently stabilized by the binding
of its PH domain to PIP products generated by PDGF-R
activity. Such a two-step process may explain the slow kinetics
of phosphorylation of APS by PDGF-R and the delayed in-
hibition of fos transcription by overexpressed APS [35]. This
also raises the possibility that APS nucleates the generation of
inhibitory signals only once it becomes membrane-bound, per-
haps by targeting receptors and/or RTK e¡ectors for ubiqui-
tin-dependent degradation enforced by c-Cbl activation.
Slap (Src-like adapter protein) provides another example of
an adapter involved in negative regulation of a speci¢c RTK
pathway. Slap consists of an SH3 domain, an SH2 module
and a COOH-terminal tail of about 100 residues [36] (Fig. 4).
Slap overexpression in quiescent ¢broblasts inhibits progres-
sion to S phase upon PDGF or serum stimulation. Con-
versely, microinjection of anti-Slap antibodies enhances the
mitogenic response of quiescent NIH 3T3 cells to either serum
or PDGF [36]. Slap binds via its SH2 domain to PTyr 579 and
581 of PDGF-R, i.e. to the sites to which c-Src also binds. In
a straightforward model, Slap may inhibit PDGF-R signaling
by competing out c-Src binding to the PDGF-R. Accordingly,
ablation of Slap SH2 domain should cause loss of Slap inhi-
bition on PDGF-R signaling. Furthermore, because a domi-
nant negative src allele inhibits PDGF-R activity in a Myc-
dependent, Ras-independent fashion, the phenotype caused by
Slap overexpression should be rescued by ectopic expression
of Myc, but not Fos and Jun. Both predictions are validated
by experimental data. The competitive inhibition model, how-
ever, can not account for the inability of overexpressed Src or
Fyn to rescue the Slap phenotype. Further genetic analysis
indicated that COOH-terminal sequences of Slap are respon-
sible for non-competitive inhibition of PDGF-activated Src
[37]. The emerging picture is that recruitment of Slap to the
PDGF-R not only inhibits Src binding but also recruits spe-
ci¢c inhibitors of Src via the Slap COOH tail (Fig. 5B).
APS and Slap are examples of negative regulators of
PDGF-R signaling whose expression has not been reported
to be modulated by receptor function. On the other hand,
feedback inhibitors, i.e. negative regulators whose expression
is transcriptionally activated by receptor signaling, are in-
volved in attenuation of RTK functions in a restricted win-
dow of time. Here we will discuss the role of SOCS and
RALT as RTK feedback inhibitors.
The family of SOCS (suppressor of cytokine signaling) pro-
teins consists of eight members which share a common struc-
tural organization, i.e. a NH2-terminal SH2 domain and a
Fig. 5. Inhibitors of mammalian RTKs target di¡erent steps of receptor signaling cascades. A: Soluble inhibitors such as Herstatin interact
with the extracellular domain of RTKs thereby inhibiting the initial steps of receptor activation (ligand binding and/or receptor dimerization).
B: Following ligand activation, inhibitors such as c-Cbl, Slap and APS-1 are recruited onto RTKs. c-Cbl enhances RTK ubiquitination, there-
by driving activated RTKs to the internalization/degradation pathway. APS-1 is phosphorylated on tyrosine, binds c-Cbl and inhibits PDGF-R
signals leading to fos transcription. Slap inhibits PDGF-R signals which lead to Myc transcription via Src activation. C: Signals from ErbB
RTKs induce transcription of ralt, whose product binds to activated ErbB receptors and inhibits signaling to the Ras/ERK pathway.
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COOH-terminal conserved region denominated SOCS box
[38] (Fig. 4). SOCS proteins are thought to inhibit cytokine
receptors signaling by binding to receptors themselves and/or
Jak kinases via their SH-2 domain in a PTyr-dependent fash-
ion [38].
Recent studies have implicated SOCS proteins also in neg-
ative regulation of a number of RTKs. SOCS-3 was identi¢ed
as a feedback inhibitor of the Stat5b pathway activated by the
insulin receptor (IR). In this study it was shown that insulin
stimulation of 3T3-L1 adipocytes induced expression of
SOCS-3 via Stat5b; SOCS-3 in turn bound to PTyr 960 of
the IR [39]. Because Stat5b itself binds to PTyr 960, it is likely
that SOCS-3 competes with Stat5b for binding to the IR, thus
inhibiting receptor signaling to this pathway [39].
SOCS-1 has been shown to bind to ligand-activated c-Kit in
a PTyr-dependent fashion, as well as to GRB-2 and to the
Rho family exchange factor Vav in a PTyr-independent fash-
ion [40]. In cells of the hematopoietic lineage socs-1 mRNA
expression is turned on by c-Kit signaling with kinetics typical
of immediate^early genes [40]. Constitutive expression of
SOCS-1 in hematopoietic cells inhibits stem cell factor
(SCF, the c-Kit ligand)-dependent proliferation, while a¡ect-
ing viability only to a limited extent. Hence SOCS-1 overex-
pression ablates proliferative but not survival signals propa-
gated by the c-Kit RTK [40]. Because its overexpression has
no consequences on c-Kit enzymatic function, it is thought
that SOCS-1 may compete with c-Kit e¡ector/s for binding
to the receptor. Alternatively, SOCS-1 may inhibit the activity
of transducers, such as Vav and GRB-2, which SOCS-1 itself
interacts with [40].
An attractive scenario is depicted by the recent observation
that the COOH-terminus of SOCS proteins binds Elongins B
and C. The elongin B/C complex was initially co-puri¢ed with
Elongin A and was shown to enhance transcription by RNA
pol II. More recently Elongin B/C was also detected in a
complex with the VHL (Von Hippel-Lindau) tumor suppres-
sor protein [41]. Binding of the Elongin B/C complex to either
Elongin A or VHL is mutually exclusive, because both Elon-
gin A and VHL contain a BC box which recognizes Elongin
C. Independently of its binding to Elongin A or VHL protein,
Elongin C can bind to Cullin-2, a putative ubiquitin E3 ligase
[41]. Elongin B, on the other hand, has a ubiquitin-like se-
quence which in other proteins is involved in the recognition
of components of the proteasome. Hence the product of the
VHL locus is thought to divert cellular proteins to the pro-
teasome machinery: mutations found in VHL patients com-
promise this function, because of the inability of mutant VHL
products to bind to the Elongin B/C complex [41,42].
Recently, the BC box has been found in the COOH-termini
of several other proteins, including the SOCS family members
as well as signaling proteins containing either WD40 or an-
kyrin repeats [43]. By analogy with the VHL proteins it has
been proposed that the BC box allows these signaling proteins
to assemble complexes which have ubiquitin E3 ligase activity
and target-associated proteins for protein degradation. SOCS-
1 can indeed be recovered in a complex with Elongin B and
C; importantly this interaction requires integrity of the SOCS-
1 BC box [43,44]. A recent report by De Sepulveda et al.
provides tantalizing evidence that SOCS-1 may direct Vav
to the ubiquitin/proteasome degradation pathway, thus inhib-
iting Vav transforming signals [45]. Vav could be found in a
complex with SOCS-1; SOCS-1 overexpression, in turn, re-
duced steady state levels of co-expressed Vav by enhancing
its degradation [45]. Signi¢cantly, inhibition of proteasome
function led to stabilization of Vav protein co-expressed
with SOCS-1 and allowed the detection of ubiquitin-conju-
gated Vav. Because Vav acts as an exchange factor for the
Rac GTPase, SOCS-1 may dampen c-Kit signaling to Rac.
Furthermore, recruitment of SOCS-1 to c-Kit may supply in
trans a ubiquitin E3 ligase activity directed toward c-Kit itself
and/or other e¡ector molecules bound to the receptor.
RALT (receptor-associated late transducer) is a recently
described feedback inhibitor of mitogenic responses propa-
gated by the ErbB-2 receptor [46] (Fig. 4). RALT mRNA
and protein are barely detectable in growth-arrested murine
¢broblasts. However strong activation of ralt transcription is
observed upon activation of the ErbB-2 kinase or serum stim-
ulation; because ralt mRNA accumulation is enhanced by
cycloheximide and abolished by actinomycin D, ralt is con-
sidered to be an immediate^early gene. RALT protein accu-
mulates during the G1 phase of the cell-cycle but disappears
abruptly as cells approach the S phase [46]. In cells treated
with proteasome inhibitors the RALT protein is stabilized
(M.F. and O.S., unpublished observations). Signi¢cantly,
RALT contains two blocks of PEST sequences (Fig. 4), usu-
ally found in proteins with rapid turn-over rates. This inte-
grated control of RALT expression (transcriptional and post-
translational) allows RALT to be expressed in a window of
the G1 phase which follows early biochemical events triggered
by mitogenic stimulation and precedes transition into S phase.
Cells engineered to express ectopic RALT at levels exceeding
2^3 fold those of the endogenous protein are impaired in their
ability to proliferate in response to ErbB-2 activation. This is
caused by accumulation of cells in the G1 phase, without any
loss of cell viability [46]. It is noteworthy that mitogenic re-
sponses to serum and PMA were not altered by RALT over-
expression, despite the ability of both agents to induce RALT
expression. Hence RALT is not a general suppressor of mito-
genic signaling, but appears to target speci¢cally receptors of
the ErbB family ([46], M.A., L.F. and O.S., unpublished ob-
servations). Disappearance of RALT upon entry into S phase
likely allows cycling cells to escape from a priori inhibition of
ErbB-2 when entering the next G1.
The ability of RALT to interfere with ErbB-2 signaling may
depend on its ability to interact with ligand activated ErbB-2
molecules. RALT interacts also with SH3 domains in vitro
and can be co-immunoprecipitated with GRB-2. Thus,
RALT behaves as an adapter: its relocation from cytosol to
the membrane compartment upon ErbB-2 activation may al-
low for regulated recruitment of inhibitors to ErbB-2 [46]. In
a search for pathways targeted by RALT inhibitory activity, it
was found that in murine ¢broblasts overexpressing RALT
activation of ERKs is altered upon ErbB-2 triggering but
not following serum or PMA stimulation. It is noteworthy
that RALT overexpression did not alter the initial pro¢le of
EGFR/ErbB-2-dependent ERK activity (i.e. up to 1 h of EGF
stimulation), whereas inhibited late ERK activation (i.e. that
observed after 3^9 h of ErbB-2 activation). This observation is
interesting because it indicates that ectopic RALT intercepts
ERK activation in the same temporal window in which also
endogenous RALT is expressed [46]. Furthermore, because
induction of RALT expression by ErbB-2 signaling is largely
controlled by the Ras/ERK pathway (O.S. and S. Alema',
unpublished observations), it appears that RALT is part of
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a feedback loop which modulates the output of signals gen-
erated by the Ras/ERK pathway (Fig. 5C).
4. An emerging picture of negative regulation of RTK signaling
in mammalian cells
The examples discussed above indicate that negative regu-
lators of RTK signaling exert their function by engaging in
protein^protein interactions. This comes as no surprise, since
the activity of RTK e¡ectors is regulated via a complex net-
work of molecular interactions [3]. The emerging role of neg-
ative regulators of RTK signaling also suggests that in many
instances we will have to refer to signals initiated by RTKs as
circuits rather than vectorial pathways.
Our understanding of the biochemistry and biology of RTK
inhibitors is still quite rudimentary. Yet, a few paradigms
emerge (Fig. 5) which are worth to be discussed: (1) more
strategies of negative signaling may be coordinately used by
a cell to modulate the output of a given RTK; (2) di¡erent
modes of interference with RTK signaling may lead to global
dampening of RTK activity or selective ablation of a de¢ned
signaling pathway; (3) inhibitors may target di¡erent tempo-
ral windows of RTK signaling; (4) the level of expression of a
given inhibitor relative to the level of receptor occupancy (i.e.
ligand availability) critically de¢nes whether an inhibitor is
involved in ¢ne tuning of RTK signaling or radical termina-
tion of receptor activity.
1. The EGFR is an example of an RTK which is sequentially
targeted by di¡erent inhibitors. Following ligand activa-
tion, the EGFR is bound by c-Cbl which promotes recep-
tor internalization and degradation [47]. EGFR signaling,
in turn, induces expression of RALT [46] which feeds back
to the receptor to inhibit its mitogenic signaling. Internal-
ized EGFR molecules are still competent for signaling to
the Ras pathway [48] but, at variance with receptors lo-
cated at the plasma membrane, are unable to promote PI
hydrolysis via PLC-Q [49]. Interestingly, RALT was shown
to co-localize with internalized EGFR/ErbB-2 chimeric re-
ceptors and to inhibit late ERK activation by ErbB-2 [46].
Hence it is possible that the sequential recruitment of c-Cbl
and RALT onto the EGFR ensures that receptors signals
are quenched in all the subcellular compartments in which
active receptors are localized.
2. Di¡erent strategies of interference with RTK activation are
likely to have evolved in order to provide £exibility of
regulation. Soluble molecules such as Herstatin [30] can
block the early steps of receptor activation and attenuate
signaling to the entire repertoire of e¡ector pathways uti-
lized by the ErbB-2 receptor. Because ErbB-2 is expressed
mainly on epithelial cells and ligands for which ErbB-2 acts
as a co-receptor are synthesized by surrounding stromal
cells, production of Herstatin by cells expressing ErbB-2
may represent an e¡ective measure to counteract ligand
activity and block receptor function. Soluble RTK antag-
onists appear to be important to impose a spatial con-
straint to the activity of RTK ligands in scenarios such
as vectorial cell migration and proliferation. On the other
hand, intracellular inhibitors which block speci¢c pathways
give the cell the option to attenuate just one of the many
signals propagated by a receptor. This strategy may be
useful to regulate kinetics and/or strength of a given signal
(when considering a linear pathway) or the activity of a
network (when considering interconnected pathways). Rel-
atively small di¡erences in signal output may have far
reaching consequences in terms of cellular responses. In
the Drosophila embryo a two fold di¡erence in the dosage
of activated Ras can have a striking impact on the develop-
ment of posterior structures [8]. Likewise, transcriptional
responses under combinatorial control may be tuned by
varying the input of just one of the di¡erent RTK signals
which act combinatorially to modulate the activity of gene
promoters.
3. The rate limiting step for the activation of inhibitors such
as Cbl, Slap and APS is essentially represented by the
availability of cognate docking sites on activated RTKs
(see above). If this event is not temporally regulated, one
can assume that this class of inhibitors acts coordinately
with positive e¡ectors to set thresholds of RTK signaling at
any given time of receptor activity. On the other hand,
RTK feedback inhibitors such as RALT and SOCS-1 epit-
omize temporally restricted regulation of RTK activity. In
this scenario, transcriptional activation of genes encoding
feedback inhibitors is a means for the cell to gauge the
accumulation of RTK signals; in turn, the ensuing accu-
mulation of RTK inhibitors is used to hold signals in
check. Such a mechanism is therefore geared to ensure an
accurate reproduction of precise patterns of signals. Accu-
mulation of feedback inhibitors may also protect cells from
perturbation, should con£icting signals be generated by
simultaneous activation of more receptors. For instance,
IL-10 treatment of monocytes induces refractoriness to
subsequent signaling by INF-K and Q, an e¡ect which has
been attributed to the induction of SOCS-3 by IL-10 [50].
RALT is induced by many mitogenic stimuli in murine
¢broblasts, although RALT overexpression inhibits only
signaling by ErbB receptors [46]. Such a seemingly redun-
dant transcriptional response may ensure that cells stimu-
lated by non-ErbB ligands become refractory to coincident
but inappropriate triggering of ubiquitously expressed
ErbB receptors.
4. Typically, ablation of the function and/or expression of
RTK inhibitors causes excess RTK signaling; conversely
overexpression of RTK inhibitors leads to severe reduction
of receptor activity. The physiological function of RTK
inhibitors may often lay in between these extreme experi-
mental conditions. Levels of receptor occupancy set the
initial threshold of signaling, which is then continuously
re¢ned by the interplay between ongoing receptor activity,
triggering of e¡ector molecules and recruitment of negative
regulators. The developmental genetics of C. elegans and
Drosophila tell us that ultimately it is the tissue context
which adjusts this balance to its own needs: in domains
where RTK activity is required, negative regulators may
simply tune signal output to make sure that the latter is
commensurate to the developmental logic. In domains in
which ligand activity is still present, and yet RTK function
would be detrimental, the job of negative regulators is to
extinguish signaling and help to delineate boundaries of
receptor activity.
5. Perspectives
Work on negative regulation of RTK signaling has lagged
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behind the exponential increase of studies dealing with the
biochemistry and biology of RTK e¡ectors. It may be safe
to assume that strategies speci¢cally aimed at the identi¢ca-
tion of RTK inhibitors may yield new members of this func-
tional class of signal regulators. The availability of the com-
plete sequence of the genomes of C. elegans, D. melanogaster
and Homo sapiens along with the use of the EST database will
allow the thorough characterization of families of RTK inhib-
itors. In particular, newly identi¢ed adapter molecules con-
taining PTB and/or SH2 domains will have to be considered
as potential signal inhibitors. Screenings for interactors of
RTKs are also likely to yield novel information about mole-
cules involved in inhibition of RTK function. Particular at-
tention will have to be given to the identi¢cation of novel
feedback inhibitors: here the identi¢cation of the full spec-
trum of RTK-dependent transcriptional responses allowed
by cDNA array technologies will be particularly helpful. Fi-
nally, the SOCS/Elongin connection and the ¢nding that c-
Cbl has E3 ubiquitin ligase activity imply that regulated intra-
cellular protein degradation is an expanding paradigm in neg-
ative signaling to RTKs.
Most of the studies on negative regulators of mammalian
RTKs have been carried out in cultured cells and are based on
overexpression experiments. It is certainly encouraging that
nullizigous mice for either socs-1 or socs-3 have phenotypes
compatible with some of the activities of these gene products
de¢ned in tissue culture experiments. Socs-1 3/3 mice die
perinatally due to unbalanced cellular responses to INF-Q
[51,52]. The socs-3 nullizigous state is embryonically lethal
at day 12^16, due to excess erythropoiesis and massive eryth-
rocytosis ; the likely cause of this pathology is thought to be
unrestrained signaling by the EPO receptor [53].
There are also indications that tumor cells may exploit the
genetic or epigenetic removal of negative regulators of RTK
signaling to acquire unrestrained proliferative ability: APS
[35] and Herstatin [30] were found to be expressed in some
tumor samples at lower levels than in normal tissues. Further-
more, v-Cbl oncoproteins are generated by loss of E3 ubiq-
uitin ligase activity: thus, v-cbl transforming activity may de-
pend on its ability to dominantly suppress c-Cbl and promote
unabated signaling by receptors with oncogenic potential
[17,54].
Future studies will have to systematically characterize the
phenotypes of mice carrying null copies of negative regulators
of RTK function. Studies aimed at the ablation of the func-
tion of RTK inhibitors in cultured cells will still be very val-
uable, as redundancy of function within families of related
proteins may mask phenotypes in KO mice.
The mechanistic basis of the function of most of the neg-
ative regulators of RTK signaling so far described is still far
from being elucidated. Ultimately it will be important to as-
sess, in reconstitution experiments, the thresholds of expres-
sion of inhibitory molecules which are required to attenuate
and possibly terminate RTK signals and compare these exper-
imental thresholds to physiological levels of expression. These
notions will have to be integrated with the in situ analysis of
the expression of RTK inhibitors during development and in
adult life. Di¡erent cell types, for instance, may adopt di¡er-
ent strategies for regulating signaling by a given RTK, thus
allowing for tissue speci¢c di¡erences in the intensity and
duration of RTK signals.
Despite our fundamental ignorance of many aspects of the
biology and biochemistry of RTK inhibitors, this rapidly
evolving ¢eld of cell signaling holds great promises for foster-
ing a better understanding of how RTK function is modu-
lated. Eventually, given the pathogenic role of deregulated
RTK activity in pathologic conditions such as cancer, it will
be possible to harness RTK inhibitors to devise novel ap-
proaches for treatment of human diseases.
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